Mediclinic International plc Mediclinic Middle East Site Visit (1452K)
December 12 2018 - 1:00AM
UK Regulatory
TIDMMDC
RNS Number : 1452K
Mediclinic International plc
12 December 2018
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic", the "Company" or the "Group")
12 December 2018
Mediclinic Middle East Site Visit
Mediclinic International plc, the international private
healthcare services group, will host a site visit for analysts and
institutional investors in Abu Dhabi and Dubai today, 12 December
2018, and tomorrow, 13 December 2018.
David Hadley, Mediclinic Middle East CEO, will briefly present
an overview of the division focusing on the following key
areas:
- Mediclinic's position as a leading private healthcare provider in the UAE
- Attractive long-term market fundamentals in the UAE
- Delivery of superior international standards in patient experience and clinical excellence
- Expansion opportunities and sustainable long-term growth
- Future plans across the continuum of care
Guidance for Mediclinic Middle East remains unchanged. The
division expects to deliver FY19 revenue growth (adjusted for the
adoption of IFRS 15) in the high single-digit percentage range
reflecting the underlying operating performance of the business and
additional bed capacity coming online in the second half of the
year. The operating leverage in the underlying business, offset to
some extent by the start-up losses associated with expansion
projects, is expected to deliver a slightly improved EBITDA margin
compared to the prior year (adjusted for the adoption of IFRS 15,
FY18: 13.0%). The Group continues to expect ongoing EBITDA margin
expansion to around 20% by FY23 given the ongoing improvements and
expansion opportunities across the region.
No new material information will be provided during the event.
Presentation material will be made available online shortly after
7am GMT on
https://ir.mediclinic.com/results-centre/presentations-and-investor-days.
About Mediclinic International plc
Mediclinic is an international private healthcare services
group, established in South Africa in 1983, with current operating
divisions in Southern Africa (South Africa and Namibia),
Switzerland and the United Arab Emirates. Its core purpose is to
enhance the quality of life of patients by providing acute care,
specialist-orientated, multi-disciplinary healthcare services.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group
plc, an LSE-listed and UK-based private healthcare group.
Mediclinic comprises 76 hospitals and 30 clinics. Hirslanden
operates 18 private hospitals and 4 clinics in Switzerland with
more than 1 900 inpatient beds; Mediclinic Southern Africa operates
48 hospitals and 4 day clinics throughout South Africa and 3
hospitals in Namibia with more than 8 100 inpatient beds in total;
and Mediclinic Middle East operates 7 hospitals and 22 clinics with
more than 900 inpatient beds in the United Arab Emirates.
Mediclinic has a primary listing on the Main Market of the LSE
in the United Kingdom, with secondary listings on the JSE in South
Africa and the NSX in Namibia.
The divisions' contributions to Group revenue for the financial
year ended 31 March 2018 were 47% by Hirslanden, 31% by Mediclinic
Southern Africa and 22% by Mediclinic Middle East.
Mediclinic has a primary listing on the Main Market of the LSE
in the United Kingdom, with secondary listings on the JSE in South
Africa and the NSX in Namibia.
For further information, please contact:
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Brett Pollard/Debbie Scott - UK
+44 (0)20 3727 1000
Sherryn Schooling - South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V
7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker: Morgan Stanley & Co International plc and
UBS Investment Bank
JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank
Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCFFWFLFFASEDE
(END) Dow Jones Newswires
December 12, 2018 02:00 ET (07:00 GMT)
Mediclinic (LSE:MDC)
Historical Stock Chart
From Apr 2024 to May 2024
Mediclinic (LSE:MDC)
Historical Stock Chart
From May 2023 to May 2024